Neoadjuvant immune checkpoint blockade triggers persistent and systemic T reg activation which blunts therapeutic efficacy against metastatic spread of breast tumors

The clinical successes of immune checkpoint blockade (ICB) in advanced cancer patients have recently spurred the clinical implementation of ICB in the neoadjuvant and perioperative setting. However, how neoadjuvant ICB therapy affects the systemic immune landscape and metastatic spread remains to be...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Oncoimmunology Ročník 12; číslo 1; s. 2201147
Hlavní autori:	Blomberg, Olga S., Kos, Kevin, Spagnuolo, Lorenzo, Isaeva, Olga I., Garner, Hannah, Wellenstein, Max D., Bakker, Noor, Duits, Danique E.M., Kersten, Kelly, Klarenbeek, Sjoerd, Hau, Cheei-Sing, Kaldenbach, Daphne, Raeven, Elisabeth A.M., Vrijland, Kim, Kok, Marleen, de Visser, Karin E.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 31.12.2023
Predmet:	Animals Breast Neoplasms - immunology Breast Neoplasms - therapy CD8-Positive T-Lymphocytes - immunology Humans Immune Checkpoint Inhibitors - therapeutic use Killer Cells, Natural - immunology Lymphocyte Activation Mice Myeloid Cells - immunology Neoadjuvant Therapy Neoplasm Metastasis T-Lymphocytes, Regulatory - immunology regulatory T cells Breast cancer metastasis myeloid cells resistance mechanisms neoadjuvant immune checkpoint blockade
ISSN:	2162-402X, 2162-402X
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!